From: Traumatic submacular hemorrhage: available treatment options and synthesis of the literature
Author | No. of eyes | Treatment | Dose | Baseline BCVA | Final BCVA | Follow-up (months) |
---|---|---|---|---|---|---|
Balughatta et al. [22] | 3 | Intravitreous C3F8 | 0.3Â ml | CF | 20/30 | 3 |
CF | 20/40 | |||||
20/60 | 20/90 | |||||
Ohji et al. [55] | 5 | Intravitreous C3F8 | 0.4Â ml | 20/400 | 20/15 | 14 |
0.4Â ml | 20/300 | 20/40 | 6 | |||
0.5Â ml | 20/2000 | 20/200 | 13 | |||
0.4Â ml | 20/400 | 20/50 | 3 | |||
0.4Â ml | 20/700 | 20/200 | 3 | |||
Gopalakrishan et al. [54] | 4 | Intravitreal C3F8 | 0.3Â ml | CF | 20/20 | 3 |
CF | 20/63 | |||||
20/125 | 20/125 | |||||
CF | 20/20 | |||||
Tsuyama et al. [48] | 1 | Intravitreous tPA + SF6 | 12.5 μg/0.05 ml + 0.3 ml | 20/70 | 20/16 | 4 |
Araújo et al. [42] | 2 | Intravitreous tPA + SF6 | 50 μg/0.05 ml + 0.3 ml | 20/63 | 20/20 | 4 |
20/200 | 20/32 | |||||
Hassan et al. [21] | 1 | Intravitreous tPA + SF6 | 75 μg/0.15 ml + 0.4 ml | 20/200 | 20/30 | 9 |
Holland et al. [49] | 2 | Intravitreous tPA + SF6 SF6 alone | 50 μg + 0.4 ml 0.4 ml | 20/125 | 20/32 | 12 |
20/100 | 20/32 | 12 | ||||
Kung et al. [41] | 1 | Intravitreal tPA + C3F8 | 50 μg + 0.3 ml |  |  |  |
Buschini et al. [38] | 2 | Subretinal tPA | 25 μg/0.1 ml | 20/100 | 20/20 | 3 |
Intravitreous tPA + SF6 | 50 μg + 0.4 ml | 20/125 | 20/63 | 5 | ||
Doi et al. [60] | 1 | Subretinal tPA | 6.9 μg/0.1 ml | HM | 20/40 | 3 |
Hillenkamp et al. [52] | 1 | Subretinal tPA + SF6 | 10–20 μg/0.05–0.1 ml | 20/125 | 20/25 | 3 |
Abdul-Salim et al. [81] | 1 | Intravitreal ranibizumab | 0.5Â mg | CF | 20/63 | 3 |